274 related articles for article (PubMed ID: 27088457)
21. Surface modification of poly(D,L-lactic-co-glycolic acid) nanoparticles with protamine enhanced cross-presentation of encapsulated ovalbumin by bone marrow-derived dendritic cells.
Han R; Zhu J; Yang X; Xu H
J Biomed Mater Res A; 2011 Jan; 96(1):142-9. PubMed ID: 21105162
[TBL] [Abstract][Full Text] [Related]
22. Activation of Antigen-Specific CD8(+) T Cells by Poly-DL-Lactide/Glycolide (PLGA) Nanoparticle-Primed Gr-1(high) Cells.
Luo WH; Yang YW
Pharm Res; 2016 Apr; 33(4):942-55. PubMed ID: 26715415
[TBL] [Abstract][Full Text] [Related]
23. PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses.
Ma W; Chen M; Kaushal S; McElroy M; Zhang Y; Ozkan C; Bouvet M; Kruse C; Grotjahn D; Ichim T; Minev B
Int J Nanomedicine; 2012; 7():1475-87. PubMed ID: 22619507
[TBL] [Abstract][Full Text] [Related]
24. Nanoparticles with CD44 Targeting and ROS Triggering Properties as Effective in Vivo Antigen Delivery System.
Liang X; Li X; Duan J; Chen Y; Wang X; Pang L; Kong D; Song B; Li C; Yang J
Mol Pharm; 2018 Feb; 15(2):508-518. PubMed ID: 29323913
[TBL] [Abstract][Full Text] [Related]
25. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
Singh D; Somani VK; Aggarwal S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
[TBL] [Abstract][Full Text] [Related]
26. A cell-penetrating peptide-assisted nanovaccine promotes antigen cross-presentation and anti-tumor immune response.
Liu X; Liu J; Liu D; Han Y; Xu H; Liu L; Leng X; Kong D
Biomater Sci; 2019 Dec; 7(12):5516-5527. PubMed ID: 31670734
[TBL] [Abstract][Full Text] [Related]
27. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming.
Zupančič E; Curato C; Paisana M; Rodrigues C; Porat Z; Viana AS; Afonso CAM; Pinto J; Gaspar R; Moreira JN; Satchi-Fainaro R; Jung S; Florindo HF
J Control Release; 2017 Jul; 258():182-195. PubMed ID: 28511928
[TBL] [Abstract][Full Text] [Related]
28. Development of poly(lactic-co-glycolic) acid nanoparticles-embedded hyaluronic acid-ceramide-based nanostructure for tumor-targeted drug delivery.
Park JH; Lee JY; Termsarasab U; Yoon IS; Ko SH; Shim JS; Cho HJ; Kim DD
Int J Pharm; 2014 Oct; 473(1-2):426-33. PubMed ID: 25079433
[TBL] [Abstract][Full Text] [Related]
29. Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular Immune Responses.
Liu Q; Jia J; Yang T; Fan Q; Wang L; Ma G
Small; 2016 Apr; 12(13):1744-57. PubMed ID: 26849717
[TBL] [Abstract][Full Text] [Related]
30. Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study.
Cruz LJ; Rosalia RA; Kleinovink JW; Rueda F; Löwik CW; Ossendorp F
J Control Release; 2014 Oct; 192():209-18. PubMed ID: 25068703
[TBL] [Abstract][Full Text] [Related]
31. Hybrid Nanoparticles Modified by Hyaluronic Acid Loading an HSP90 Inhibitor as a Novel Delivery System for Subcutaneous and Orthotopic Colon Cancer Therapy.
Pan C; Zhang T; Li S; Xu Z; Pan B; Xu S; Jin S; Lu G; Yang S; Xue Z; Chen P; Shen X; Wang F; Xu C
Int J Nanomedicine; 2021; 16():1743-1755. PubMed ID: 33688189
[TBL] [Abstract][Full Text] [Related]
32. "Pathogen-mimicking" nanoparticles for vaccine delivery to dendritic cells.
Elamanchili P; Lutsiak CM; Hamdy S; Diwan M; Samuel J
J Immunother; 2007; 30(4):378-95. PubMed ID: 17457213
[TBL] [Abstract][Full Text] [Related]
33. Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells.
Maiolino S; Russo A; Pagliara V; Conte C; Ungaro F; Russo G; Quaglia F
J Nanobiotechnology; 2015 Apr; 13():29. PubMed ID: 25888948
[TBL] [Abstract][Full Text] [Related]
34. PLGA nanoparticles modified with a TNFα mimicking peptide, soluble Leishmania antigens and MPLA induce T cell priming in vitro via dendritic cell functional differentiation.
Margaroni M; Agallou M; Kontonikola K; Karidi K; Kammona O; Kiparissides C; Gaitanaki C; Karagouni E
Eur J Pharm Biopharm; 2016 Aug; 105():18-31. PubMed ID: 27235727
[TBL] [Abstract][Full Text] [Related]
35. Development and mechanistic insight into enhanced cytotoxic potential of hyaluronic acid conjugated nanoparticles in CD44 overexpressing cancer cells.
Saneja A; Nayak D; Srinivas M; Kumar A; Khare V; Katoch A; Goswami A; Vishwakarma RA; Sawant SD; Gupta PN
Eur J Pharm Sci; 2017 Jan; 97():79-91. PubMed ID: 27989859
[TBL] [Abstract][Full Text] [Related]
36. In Vitro Evaluation of the Biological Responses of Canine Macrophages Challenged with PLGA Nanoparticles Containing Monophosphoryl Lipid A.
Guldner D; Hwang JK; Cardieri MC; Eren M; Ziaei P; Norton MG; Souza CD
PLoS One; 2016; 11(11):e0165477. PubMed ID: 27835636
[TBL] [Abstract][Full Text] [Related]
37. Chlamydia trachomatis recombinant MOMP encapsulated in PLGA nanoparticles triggers primarily T helper 1 cellular and antibody immune responses in mice: a desirable candidate nanovaccine.
Fairley SJ; Singh SR; Yilma AN; Waffo AB; Subbarayan P; Dixit S; Taha MA; Cambridge CD; Dennis VA
Int J Nanomedicine; 2013; 8():2085-99. PubMed ID: 23785233
[TBL] [Abstract][Full Text] [Related]
38. Recruitment of bone marrow CD11b
Yang YW; Luo WH
Sci Rep; 2017 Mar; 7():44691. PubMed ID: 28317931
[TBL] [Abstract][Full Text] [Related]
39. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
40. Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin.
Lee H; Ahn CH; Park TG
Macromol Biosci; 2009 Apr; 9(4):336-42. PubMed ID: 19006195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
